The short version of Pentapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-17 and is reviewed periodically as new material appears.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
== L == Lamina A layer of neurons in a neural structure. In the spinal cord and cerebral cortex, laminae are functionally and anatomically distinct. Lateral geniculate nucleus (LGN) A relay center in the thalamus that receives input from the retina and sends visual information to the visual cortex. Lateral inhibition A neural mechanism in which an excited neuron reduces the activity of its neighbors. Enhances contrast in sensory systems such as vision and touch. Lateral sulcus A deep groove in the cerebral cortex that separates the frontal lobe and parietal lobe from the temporal lobe. Learning The acquisition of new knowledge or skills through experience, study, or teaching. In neuroscience, learning is linked to synaptic plasticity and neural circuit changes. Learning A neurobiological process through which experience induces lasting changes in the nervous system, leading to the acquisition or modification of behavior, knowledge, or skills. Lentiform nucleus A structure within the basal ganglia composed of the putamen and globus pallidus, involved in motor control and learning. Lesion Damage or abnormal change in brain tissue, caused by injury, stroke, disease, or surgery. Lesion studies are used to investigate brain function. Levodopa A precursor to dopamine used in the treatment of Parkinson’s disease. It crosses the blood–brain barrier and is converted to dopamine in the brain. Limbic system A group of interconnected brain structures involved in emotion, motivation, memory, and olfaction. Includes the amygdala, hippocampus, and cingulate cortex.
xv. ISBN 978-1-62683-043-1. Retrieved March 22, 2021. Siddiqi, Asif A. (2000). Challenge to Apollo: the Soviet Union and the space race, 1945–1974 (PDF). Washington, D.C.: National Aeronautics and Space Administration, NASA History Div. Retrieved February 10, 2026. Siddiqi, Asif A. (2003). Sputnik and the Soviet Space Challenge. Gainesville: University Press of Florida. ISBN 0-8130-2627-X. Siddiqi, Asif A. (2003). The Soviet Space Race with Apollo. Gainesville: University Press of Florida. ISBN 0-8130-2628-8. Stocker, Jeremy (2004). Britain and Ballistic Missile Defence, 1942–2002. London: Frank Case. pp. 12–24. ISBN 0-7146-5696-8. Swenson, Loyd S. Jr.; Grimwood, James M.; Alexander, Charles C. (1966). This New Ocean: A History of Project Mercury. NASA. ISBN 1-934941-87-5. Retrieved January 8, 2023. Turnhill, Reginald (2004). The Moonlandings: An Eyewitness Account. New York: Cambridge University Press. ISBN 0-521-81595-9. Pervushin, Anton (2011). 108 minutes which changed the world (in Russian). Эксмо. ISBN 978-5-699-48001-2.
A honey bee that is away from the hive foraging for nectar or pollen will rarely sting, except when stepped on or roughly handled. Honey bees will actively seek out and sting when they perceive the hive to be threatened, often being alerted to this by the release of attack pheromones (below). Although it is widely believed that a worker honey bee can sting only once, this is only partially true: although the stinger is in fact barbed so that it lodges in the victim's skin, tearing loose from the bee's abdomen and leading to its death in minutes, this only happens if the skin of the victim is sufficiently thick, such as a mammal's. Honey bees are the only hymenoptera with a strongly barbed sting, though yellow jackets and some other wasps have small barbs. The venom of the honeybee contains histamine, mast cell degranulating peptide, melittin, phospholipase A2, hyaluronidase and acid phosphatase. The three proteins in honeybee venom that are important allergens are phospholipase A2, hyaluronidase and acid phosphatase. In addition, the polypeptide melittin is also antigenic. Bumblebee venom appears to be chemically and antigenically related to honeybee venom. Bees with barbed stingers can often sting other insects without harming themselves. Queen honeybees and bees of many other species, including bumblebees and many solitary bees, have smoother stingers with smaller barbs and can sting mammals repeatedly. The sting's injection of apitoxin into the victim is accompanied by the release of alarm pheromones, a process which is accelerated if the bee is fatally injured.
A rarer form of hyperphenylalaninemia is tetrahydrobiopterin deficiency, which occurs when the PAH enzyme is normal, and a defect is found in the biosynthesis or recycling of the cofactor tetrahydrobiopterin (BH4). BH4 is necessary for proper activity of the enzyme PAH, and this coenzyme can be supplemented as treatment. Those with this form of hyperphenylalaninemia may have a deficiency of tyrosine (which is created from phenylalanine by PAH), in which case treatment is supplementation of tyrosine to account for this deficiency. Levels of dopamine can be used to distinguish between these two types. Tetrahydrobiopterin is required to convert Phe to Tyr and is required to convert Tyr to L-DOPA via the enzyme tyrosine hydroxylase. L-DOPA, in turn, is converted to dopamine. Low levels of dopamine lead to high levels of prolactin. By contrast, in classical PKU (without dihydrobiopterin involvement), prolactin levels would be relatively normal. As of 2020, tetrahydrobiopterin deficiency was known to result from defects in five genes.
Sources: en.wikipedia.org
=== 1980s === Kidder reprised her role as Lois Lane in Superman II (1980), though she publicly disagreed with the decision of producers Alexander Salkind and Ilya Salkind to replace Richard Donner as director. Superman II was also a box-office hit, grossing $108 million in the United States. Through her appearances in the Superman films, Kidder maintained a close friendship with her co-star Christopher Reeve, which lasted from 1978 until his death in 2004: "When you're strapped to someone hanging from the ceiling for months and months, you get pretty darned close," Kidder told CBS. "He was such a huge part of my life... He was complicated, very smart, really smart, and he knew he'd done something meaningful. He was very aware of that and very happy with that role." Also in 1980, she appeared in Paul Mazursky's romantic comedy Willie & Phil, playing one-third of a love triangle opposite Michael Ontkean and Ray Sharkey. Kidder starred in the Canadian comedic road movie Heartaches (1981), portraying a free-spirited woman who helps an acquaintance raise her child. Vincent Canby of The New York Times noted: "Nothing happens in Heartaches that isn't telegraphed 15 minutes ahead of time, but Miss Kidder and Miss [Annie] Potts are good fun to watch, not because they convince you of the reality of their characters but because they handle their assignments with such unbridled, comic, actressy enthusiasm." She then starred opposite Richard Pryor in the comedy Some Kind of Hero (1982), about a Vietnam War veteran who attempts to re-assimilate into civilian life.
It was also formerly used in veterinary medicine as a general anesthetic but is not considered acceptable for anesthesia or euthanasia of small animals owing to adverse effects. It is also still used as a sedative prior to EEG procedures, as it is one of the few available sedatives that do not suppress epileptiform discharges. In therapeutic doses for insomnia, chloral hydrate is effective within 20 to 60 minutes. In humans it is metabolized within 7 hours into trichloroethanol and trichloroethanol glucuronide by erythrocytes and plasma esterases and into trichloroacetic acid in 4 to 5 days. It has a very narrow therapeutic window making this drug difficult to use. Higher doses can depress respiration and blood pressure. Tolerance to the drug develops after a few days of use.
Feoktist I. Bogoyavlenskiy (1933–1935) Vasiliy V. Evlampiev (1935–1939) Faizi F. Faizyllin (1958–1960) Boris A. Arbuzov (1941–1950) Arkadiy N. Pudovik (1950–1958) Faizi F. Faizyllin (1958–1960) Vera F. Toropova (1960–1965) Alexander I. Kostromin (1965–1968) Alexander I. Konovalov (1968–1972) Irina V. Konovalova (1972–1987) Galina A. Chmutova (1987–1992) Nikolai A. Ulakhovich (1992–2000) Vladimir I. Galkin (since 2000– until present) Department of Analytical Chemistry Department of High Molecular and Organoelement Compounds Department of Inorganic Chemistry Department of Organic Chemistry Department of Physical Chemistry Department of Chemical Education Department of Environmental Chemistry Department of Applied Chemistry Department of Stereochemistry Division for Analytical Chemistry Division for Inorganic Chemistry and Coordination chemistry Division for Organic Chemistry Division for Physical Chemistry Division for Organoelement Compounds Division for Stereochemistry Division for Applied Chemistry Division for Environmental Chemistry
As of 2020 machine learning – and especially deep machine learning – has recently become more commonly used in phenotyping. Computer vision using machine learning has made great strides and is now being applied to leaf phenotyping and other phenotyping jobs typically performed by human eyes. Pound et al. 2017 and Singh et al. 2016 are prominent examples of early successful application and demonstration of the general usability of the process across multiple target plant species. These methods work better when provided with large, publicly available open data sets. Speed breeding is introduced by Watson et al. 2018. Classical (human performed) phenotyping during speed breeding is also possible, using a procedure developed by Richard et al. 2015. As of 2020 it is highly anticipated that SB and automated phenotyping will, combined, produce greatly improved outcomes – see Phenotyping and artificial intelligence above.
== In nuclear power reactors == In any operating nuclear reactor containing 238U, some plutonium-239 will accumulate in the nuclear fuel. Unlike reactors used to produce weapons-grade plutonium, commercial nuclear power reactors typically operate at a high burnup that allows a significant amount of plutonium to build up in irradiated reactor fuel. Plutonium-239 will be present both in the reactor core during operation and in spent nuclear fuel that has been removed from the reactor at the end of the fuel assembly's service life (typically several years). Spent nuclear fuel commonly contains about 0.8% plutonium-239. Plutonium-239 present in reactor fuel can absorb neutrons and fission just as uranium-235 can. Since plutonium-239 is constantly being created in the reactor core during operation, the use of plutonium-239 as nuclear fuel in power plants can occur without reprocessing of spent fuel; the plutonium-239 is fissioned in the same fuel rods in which it is produced. Fissioning of plutonium-239 provides more than one-third of the total energy produced in a typical commercial nuclear power plant. Reactor fuel would accumulate much more than 0.8% plutonium-239 during its service life if some plutonium-239 were not constantly being "burned off" by fissioning. A small percentage of plutonium-239 can be deliberately added to fresh nuclear fuel. Such fuel is called MOX (mixed oxide) fuel, as it contains a mixture of uranium dioxide (UO2) and plutonium dioxide (PuO2). The addition of plutonium-239 reduces the need to enrich the uranium in the fuel.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.